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The health-related quality of life (HRQoL) outcomes in HIV-infected, treatment-naive patients starting 
different HAART regimens in a 3-year, randomised, multinational trial were compared. HRQoL was 
measured in a subgroup of patients enrolled in the INITIO study (153/911), using a modified version of 
the MOS-HIV questionnaire. The regimens compared in the INITIO trial were composed by two NRTIs 
(didanosine+stavudine) plus either a NNRTI (efavirenz) or a PI (nelfinavir), or both (efavirenz+nelfinavir). 
Primary HRQoL outcomes were Physical and Mental Health Summary scores (PHS and MHS, respectively). 
During follow up, an increase of PHS score was observed in all treatment arms. The MHS score remained 
substantially unchanged with the 4-drug combination and showed with both NNRTI- and PI-based 3-drug 
regimens a marked trend toward improvement, which became statistically significant when a multiple 
imputation method was used to adjust for missing data. Overall, starting all the combination regimens 
compared in the INITIO study was associated to a maintained or slightly improved HRQOL status, 
consistently with the positive immunological and virological changes observed in the main study. The 
observed differences in the MHS indicate a possible HRQoL benefit associated to the use of 3-drug, 2-class 
regimens and no additional benefit for the use of 4-drug, 3-class regimens, confirming that 3-drug, 2-class 
regimens which include 2NRTIs plus either a NNRTI or a PI should be preferred as initial treatment of HIV 
infection.  
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INTRODUCTION 
 
Guidelines recommendations for treatment in HIV infection are generally based on the 
information obtained in clinical trials. Traditionally, this has been mostly represented by 
immunological and virological response and by a safety profile defined through the adverse 
events occurring during the study.  
Such measures, however, only provide an incomplete assessment of the complex effects of 
treatment, and lack a patient-centered perspective.  Health Related Quality of life  (HRQoL) 
has been recently recognised by guidelines as a main therapeutic objective and is therefore 
increasingly used in the comparison of anti-HIV drugs and as an additional or independent 
measure of drug evaluation1. 
We here report the results of a specific QoL substudy nested in the large, multinational 
INITIO trial, which compared different treatment strategies for starting and continuing HIV 
treatment in naive patients. The INITIO-QoL substudy aimed to detect differences in 
patient’s HRQoL between the three study treatment groups. Its final purpose was to 
provide, by patient’s reported outcome (pro), potentially relevant additional information, 
alongside clinical data, for making decisions on medical treatment.  
 
 
METHODS 
 
Study treatments and patients 
INITIO was a randomised, multinational, open-label study conducted at outpatient clinic 
sites in Australia, Brazil, Canada, New Zealand and 17 European countries2. The trial 
compared three different treatment strategies based on the use of non-nucleoside reverse 
transcriptase inhibitors (NNRTI) or protease inhibitors (PI) for starting and continuing HIV 
treatment in naive patients. Participants (n=911) were randomised in a 1:1:1 ratio to a 3-
drug, NNRTI-based regimen [didanosine+stavudine+efavirenz (ddI/d4T/EFV)], a 3-drug, 
PI-based regimen [didanosine+stavudine+nelfinavir (ddI/d4T/NFV)], or a 4-drug, NNRTI- 
and PI-based regimen [didanosine+stavudine+efavirenz+nelfinavir (ddI/d4T/EFV/NFV)].  
Investigators could substitute one drug with another from the same class for intolerance 
and so continue the allocated drug classes. This was not regarded as a regimen change. 
The selection of regimens after second therapeutic failure in the three-drug arms or first 
failure in the four-drug arm was at the discretion of the investigators.  
The countries participating in the INITIO-QoL substudy were Australia, Brazil, Canada, 
Italy, New Zealand and UK.  Patients enrolled in the main study in these countries were 
offered participation in this substudy and evaluated over 3 years for HRQoL. Each site 
obtained ethics committee approval and participants provided written informed consent. 
 
Data Collection 
Baseline demographic data included gender, age, route of transmission and duration of 
HIV disease. Clinical information included HIV disease status (CDC disease stage), HIV RNA 
viral load (VL) and CD4+ cell count. Trial visits for CD4 count, viral load, clinical symptoms, 
treatment status and adverse events were performed at baseline, at weeks 4, 8, 12, and 
every 12 weeks thereafter, with a final assessment at three years of follow-up. HRQoL 
assessments followed the same time points. Data collection for the substudy was 
coordinated by the National Italian Coordinating Center (Istituto Superiore di Sanità), 
where the analysis of the substudy was also performed. 
 
HRQoL Measurement 
Quality of life was assessed using  the medical Outcomes Study (MOS)-HIV questionnaire, 
which represents a brief, comprehensive and HIV-targeted measure of health-related QoL 
3,4. The questionnaire is structured in 33 questions grouped into nine scales from which 
two synthetic indexes can be obtained, concerning the physical and the mental 
component: Physical Health Summary (PHS) and  Mental Health Summary (MHS) , 
respectively.  
Each scale examines a specific aspect of QoL: physical functioning (PF), bodily-pain (BP), 
vitality (VT), role functioning (RF), general health perceptions (GH), cognitive functioning 
(CF), health distress (HD), mental health (MH) and social functioning (SF).  
The MOS-HIV questionnaire was validated in all the countries involved in the INITIO-QoL 
substudy as a measure of functional status and well-being in people with HIV disease, with 
extensive testing for reliability and validity5-6. The psychometric performance of the scales 
was retested on the substudy population performing the following evaluations: 1) internal 
consistency reliability, using Cronbach’s alpha (value required: ≥0.70), 2) convergent 
validity, measured through the linear correlation between each item and its respective 
scale (correlation coefficient value requested: ≥0.40); 3) discriminant validity [correlation 
of questions with their respective scales should be higher than correlations with the other 
scales (≥2SE)]; and, 4) inter-scales correlation (value requested: correlation range of 
0.40-0.80).  
 
Statistical Analysis 
The main trial sample size was calculated on the basis of trial endpoints, represented by 
virological and immunological efficacy. Additional enrollment in the HRQol substudy was 
free and no predetermined sample size was calculated for this substudy, which represents 
a secondary analysis of an exploratory nature. The aim of this sub-study was to compare 
the effects of the three different strategies on health related quality of life through the 
whole follow up period.  
HRQoL analyses were performed according to both an “intention-to-treat” (ITT) and an “on 
treatment” (OT) approach. The OT analysis was based on QoL data observed on first 
allocated regimen.  
Baseline characteristics (demographic, clinical and HRQoL) were compared between 
treatment groups with the F-Fisher test for continuous variables and with Pearson’s 2 test 
for categorical variables. 
Patients with incomplete data were not excluded from the analysis, which was carried out 
based on all the available patient information.   
To evaluate the nature of the missing data occurred in the substudy, mean changes of 
both PHS and MHS scores were assessed in patients with/without complete data. For this 
analysis, patients who had final information available at the end of the study were 
considered to have complete data also if one or more observations were missing between 
baseline and end of the study. A general linear mixed model was used to evaluate the 
differences between treatments in terms of changes from baseline in PHS and MHS indexes 
over follow-up. Change from baseline in both PHS and MHS scores was considered as an 
outcome in this model, with treatment regimens and time of follow-up considered as 
independent variables.  
Missing data were handled with a multiple imputation (MI) method, and the analyses were 
repeated  after the imputation had been done.   
Statistical calculations were performed using SAS statistical package, version 8.2 (SAS 
Institute, Inc., Cary, North Carolina, USA). 
 
RESULTS 
 
1. Baseline characteristics 
Overall, 153 patients participated to the QoL substudy, from Italy (35%), Australia (28%), 
UK (27%), Canada (7%) and Brazil (3%) (figure 1). There were no significant differences 
at baseline between treatment groups with respect to demographic and clinical variables 
(Table 1). The baseline characteristics of these patients were similar to those of the 911 
patients randomized to the main INITIO study. The percentages of patients which agreed 
to join the substudy were, for each of three treatment groups, 16% (EFV), 17% (NFV) and 
17% (EFV/NFV).  
Baseline QoL values for all the scales and for synthetic indexes (PHS and MHS) were 
similar for the three treatment groups (Table 1). The tests on psychometric assumptions 
showed a good reliability (Cronbach’s alpha ≥0.80 for all scales) and satisfied assumptions 
for construct validity (data non shown).  
 
2. Physical and mental health summary indexes  
During follow-up, an increase of PHS score (mean change from baseline) was observed in 
all treatment arms, while MHS increased only in both the three-drug regimen groups. Mean 
changes from baseline in PHS and MHS at one, two and three years are reported in figure 
2.  
The nature of missing data was assessed analysing the plots of PHS and MHS mean 
changes from baseline in patients with and without complete data, respectively. The 
observed results showed that the missing data operated differently in the two groups (data 
not shown). We therefore concluded that missing data in this study could be considered as 
MAR, allowing use of the general linear mixed application and of a multiple imputation 
strategy.  
The results of the general linear mixed model showed no statistically significant differences 
over time in PHS scores among the treatment arms. The results for the MHS scores 
showed a trend toward a better response with both the 3-drug regimens, compared to the 
4-drug regimen: differences in MHS score were 2.6 (95% CI: -0.4 - 5.6) between EFV and 
EFV/NFV (p=0.09); and 2.6 (95% CI -0.3 - 5.6) between NFV and EFV/NFV (p=0.08).   
The above trend for MHS scores achieved statistical significance with the MI imputation 
method: differences with the EFV/NFV arm for EFV and NFV arms were, respectively 3.8 
(95% CI 0.6 - 6.7, p=0.02) and 3.3  (95% CI 0.1 - 6.4, p=0.04). 
The results of OT analyses regarding changes from baseline in MHS and PHS scores were 
similar to those provided by the ITT analysis (data not shown). 
 
 
DISCUSSION 
 
This exploratory substudy on quality of life in HIV-infected, antiretroviral naive starting 
different HAART regimens showed that the three-drug regimens studied produced, during 
three years of follow up, a general and sustained improvement of HRQoL, as assessed by 
mental and physical health summary scores. The four-drug regimen was associated to 
positive changes in the physical component of QoL, but not in the mental component of 
QoL.  
When the extent of changes was compared among the three treatment groups, the results 
showed that changes in the mental health dimension were similar between the two three-
drug regimens, and confirmed that both of them were superior to the four-drug regimen. 
No advantage for the mental component was therefore evident from starting with a four–
drug regimen including both a PI and a NNRTI, because MHS scores remained in this 
group similar to baseline values or decreased below such values at some points of follow-
up.  
In terms of changes of physical health dimension, no statistically differences were found 
among of three therapeutic strategies.  
Our results are consistent with those by A. Casado, X. Badia et al, who also showed 
equivalence in HRQoL between different triple combinations in a clinical trial7, where, 
however, patients with AIDS-defining diseases were not included and the follow-up period 
was only 1 year.  
In the interpretation of our results, it is important to define the clinical relevance of the 
differences observed in MHS and PHS. The 2.6 point advantage in MHS observed for the 
three-drug combinations is clearly lower than the average differences observed between 
patients with and without AIDS, which amounted to 6.7 points in PHS and 4.5 points in 
MHS8 that are considered clinically significant. However, in the INITIO study, the vast 
majority of patients were asymptomatic, and all the treatments studied had the same 
clinical and immunological efficacy. It is therefore likely that the QoL differences that we 
observed were mostly due to side effects of drugs and adherence with complex therapeutic 
regimens. The differences observed, even if statistically significant, may therefore either 
have no clinical relevance, suggesting similar QoL profile for all regimens, or indicate actual 
subtle differences attributable to different treatment profiles and captured by the HRQoL 
instrument.  
In the patients belonging to the substudy, a traditional analysis of toxicity (grade>=3) did 
not reveal any differences among the three treatment that could explain the observed 
differences in QoL. However, grade 1 and 2 adverse events, also expected to affect the 
HRQoL, were not collected in this trial.  
Our result therefore can be considered as preliminary evidence of QoL differences to be 
confirmed.  
The causes for the lower performance of the four-drug regimen in terms of mental health 
can only be hypothesized. The lower quality of life observed for the mental component 
with the 4-drug regimen might be in some way related to psychological effects related to 
the more complex therapeutic scheme, the larger number of pills required and/or the 
difficulties related to maintaining adherence with the regimen. No studies have 
investigated this issue, and further research on this argument would be useful. What is 
missing in the field is a list of patient-reported symptoms which better define all the 
heterogeneous components that affect QoL in patients receiving treatment in the HAART 
era9-13. 
It is important to note that, consistently with the clinical, immunological and virological 
results of the main study, this HRQoL evaluation did not show any benefit for starting 
antiretroviral treatment with a four-drug combination compared to starting with three-drug 
regimens, confirming that 3-drug, 2-class regimens which include 2NRTIs plus either a 
NNRTI or a PI should be preferred as initial treatment of HIV infection.  
Furthermore, the HRQoL increases from baseline observed with these regimens can be 
considered as particularly positive, indicating that no major negative effect on quality of life 
is evident in patients starting combination antiretroviral regimens.    
A possible limitation of the study is represented by patients with missing information; we 
addressed this phenomenon using imputation methods to treat missing data. However, it 
has to be considered that this is a common problem in clinical trials, and few studies have 
obtained QoL information over a follow up of similar length. Future studies which include 
QoL evaluations or other patient-reported outcomes should address this problem trying to 
maintain a complete data collection over the entire follow up period.  
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Figure 1 
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52 assigned EFV/NFV 
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Missing QoL measurements at 3 
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Missing QoL measurements at 3 
years: 22 (42%) 
 
1 did not reach year 3 
4 died before year 3 
3 lost to follow-up before year 3 
14 QoL measures missing 
 
28 (58%) included in analysis  
at the end of follow-up 
 
34 (64%) included in analysis  
at the end of follow-up 
 
30 (58%) included in analysis  
at the end of follow-up 
153 patients included in the 
QoL substudy 
 
35%  Italy  
28%  Australia/NZ  
27%  UK  
7%  Canada  
3%  Brazil 
Table 1. Baseline characteristics 
 
EFV NFV EFV/NFV 
 
ALL 
p 
value 
 
N°, randomized   
 
48 
 
53 
 
52 
 
153 
 
 
Gender:  
-Female: n (%) 
-Male: n (%) 
 
 
11 (22.9) 
37 (77.1) 
 
 
10 (18.9) 
43 (81.1) 
 
 
12 (23.1) 
40 (76.9) 
 
 
33(21.6) 
120 (78.4) 
 
 
0.84 * 
 
Age (years): 
-All, meanSD (n ,range) 
mediana 
 
 
39.711.1 (48, 20-63) 
40 
 
 
37.38.7 (53, 22-56) 
35 
 
 
38.49.9 (52, 21-62) 
37 
 
 
38.59.8 (153, 20-63) 
36 
 
 
0.98 ** 
 
Predominant risk factor: n (%) 
-Homo / bisexual: 
-I.V.drug use: 
-Heterosexual: 
-Other/unknown: 
 
 
25 (52.1) 
2 (4.2) 
19 (39.6) 
2 (4.2) 
 
 
23 (43.3) 
9 (17.0) 
20 (37.8) 
1  (1.9) 
 
 
24 (46.1) 
6 (11.5) 
21 (40.4) 
1  (1.9) 
 
 
72 (47.1) 
17 (11.1) 
60 (39.2) 
4 ( 2.6) 
 
 
 
0.23 * 
 
CD4+/mm3  
mean SD (n, range) 
median 
 
 
164168 (48, 0-851) 
106 
 
 
210153 (53, 10-630) 
193 
 
 
204201 (52, 4-1056) 
168 
 
 
193175 (153, 0-1056) 
168 
 
 
1.00 ** 
 
HIV-RNA cp/ml (log10) 
mean SD (n, range) 
median 
 
 
5.20.6(48, 3.4-6.1) 
5.3 
 
 
5.00.6 (53, 3.7-5.9) 
5.1 
 
 
5.10.7 (52, 3.4-6.3) 
5.2 
 
 
5.10.6 (153, 3.4-6.3) 
5.2 
 
 
1.07 ** 
 
Stage at randomization: n (%)                    
-CDC A  
-CDC B 
-CDC C 
 
 
24 50.0) 
10 (20.8) 
14 (29.2) 
 
 
34 (64.2) 
9 (17.0) 
10 (18.9) 
 
 
21 (40.4) 
18 (34.6) 
13 (25.0) 
 
 
79 (51.6) 
37 (24.2) 
37 (24.2) 
 
 
0.10 * 
 
General health  
mean SD (n, range) 
 
 
4227 (46, 0-95) 
 
 
3828 (51, 0-100) 
 
 
4226 (50, 0-100) 
 
 
4127 (147, 0-100) 
 
 
0.65** 
 
Bodily pain 
mean SD (n, range) 
 
 
8025 (47, 22-100) 
 
 
7624(53, 11-100) 
 
 
7429 (52, 11-100) 
 
 
7626 (152, 11-100) 
 
 
0.50** 
 
Physical functioning 
mean SD (n, range) 
 
 
7924 (48, 17-100) 
 
 
7030 (50, 0-100) 
 
 
7926 (52, 17-100) 
 
 
7627 (150, 0-100) 
 
 
0.14** 
 
Physical role limitations 
mean SD (n, range) 
 
 
7837 (47, 0-100) 
 
 
6745 (51, 0-100) 
 
 
7043 (51, 0-100) 
 
 
7142 (149, 0-100) 
 
 
0.41** 
 
Social functioning 
mean SD (n, range) 
 
 
7231 (48, 0-100) 
 
 
7531 (52, 0-100) 
 
 
7332 (52. 0-100) 
 
 
7331 (152, 0-100) 
 
 
0.88** 
 
Mental health 
mean SD (n, range) 
 
 
6520 (48, 24-100) 
 
 
6323 (52, 0-100) 
 
 
6120 (52, 8-96) 
 
 
6321 (152, 0-100) 
 
 
0.68** 
 
Vitality 
mean SD (n, range) 
 
 
5624 (47, 5-100) 
 
 
5522 (53, 15-100) 
 
 
5826 (51, 0-100) 
 
 
5624 (151, 0-100) 
 
 
0.85** 
 
Health distress 
mean SD (n, range) 
 
 
6726 (47, 5-100) 
 
 
7126 (53, 0-100) 
 
 
7128 (51, 0-100) 
 
 
7027 (151, 0-100) 
 
 
0.64** 
 
Cognitive functioning 
mean SD (n, range) 
 
 
8220 (47, 10-100) 
 
 
7823 (53, 15-100) 
 
 
8023 (51, 10-100) 
 
 
8022 (151, 10-100) 
 
 
0.69** 
 
Quality of life 
mean SD (n, range) 
 
 
6026 (46, 0-100) 
 
 
5628 (52, 0-100) 
 
 
5924 (51, 0-100) 
 
 
5826 (149, 0-100) 
 
 
0.67** 
 
Health transition  
mean SD (n, range) 
 
 
6227 (46, 0-100) 
 
 
5921 (53, 0-100) 
 
 
5921 (52, 0-100) 
 
 
6023 (151, 0-100) 
 
 
0.81** 
 
Physical health summary scores  
mean SD (n, range) 
 
 
5011 (44, 25-63) 
 
 
4613 (47, 19-67) 
 
  
4812 (48, 22-64) 
 
 
4812 (139, 19-67) 
 
 
0.45** 
 
Mental health summary scores 
mean SD (n, range) 
 
 
4910 (44, 30-83) 
 
 
4810 (47, 19-65) 
 
 
509 (48, 33-76) 
 
 
4910 (139, 19-83) 
 
 
0.75** 
 
* 2 test;  **F-Fisher test 
 
Figure 2 
 
 
 
  
 
